Royalty income up 15% YoY A$65m Interest income A$12m NPAT without any one-time revenue A$30m Corporate & admin costs only A$6m R&D investment in NNZ-2591 A$36m DAYBUE revenue since launch in 2023 A$510m THE 2025 NUMBERS – GROWING SUSTAINABLE INCOME STRONG DAYBUE® CASH FLOWS ENABLE PURSUIT OF STEP-CHANGE IN VALUE FROM NNZ-2591 Large potential upside for shareholders is enabled by financial strength 5 Phelan-McDermid syndrome Pitt Hopkins syndrome Hypoxic Ischemic Encephalopathy (HIE) NNZ-2591 (ercanetide) indications prioritised for maximum commercial impact Long-term income growth from DAYBUE® (trofinetide) A$510m income from DAYBUE since launch in 2023 A$296 million cash as at 31 Dec 2025 * Rett and Fragile X syndromes are licensed to Acadia, with same economics to Neuren as trofinetide; Neuren retains worldwide rights to all other indications Angelman syndrome, Prader-Willi Syndrome, SYNGAP1, Rett syndrome (Acadia)*, Fragile X syndrome (Acadia)* The 2025 numbers – growing sustainable income • A$65m royalty income up • Interest income A$12m • A$30m NPAT without any • Corporate & admin costs only A$ • R&D investment in NNZ-2591 A$ • A$510m DAYBUE reven - 27 56 65 15 205 157 16 238 221 82 2022 2023 2024 2025 Total Income (including net derivative and FX gain/loss) Royalty One-offs Net Financial income* *Finance Income + net gain / (loss) on financial derivatives + net FX gain / (loss), excluding FX translation * Finance Income + net gain / (loss) on financial derivatives + net FX gain / (loss), excluding FX translation Ex-NA upfront & 1st commercial sale milestone 1st sales milestone & PRV sale Neuren Pharmaceuticals Limited Annual Report 2025 1
RkJQdWJsaXNoZXIy MjE2NDg3